Abstract Thirty-six patients with Raynaud's disease (RD) were treated with a low dosage of β-blockers, atenolol (50 mg/day) or propranolol (20 mg/day). Previous data have suggested that the pathophysiology of RD may be mediated by presynaptic β-adrenoceptors. In this research we report that chronic β-blocker treatment, at low dosage, can prevent the cold-induced vasospasm. The majority of patients (28) responded to atenolol, and 8 patients refractory to atenolol responded to propranolol.
β-Blockers: A new therapeutic approach to Raynaud's disease
MONTISCI, ROBERTO;PETRUZZO, PALMINA
1987-01-01
Abstract
Abstract Thirty-six patients with Raynaud's disease (RD) were treated with a low dosage of β-blockers, atenolol (50 mg/day) or propranolol (20 mg/day). Previous data have suggested that the pathophysiology of RD may be mediated by presynaptic β-adrenoceptors. In this research we report that chronic β-blocker treatment, at low dosage, can prevent the cold-induced vasospasm. The majority of patients (28) responded to atenolol, and 8 patients refractory to atenolol responded to propranolol.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
